EL7.AI
StocksMedium•16 November 2026•
4 min read

CG Oncology Drug Cuts Bladder Cancer Recurrence Risk 68% in Phase 3 Trial

Key Facts

1Cretostimogene reduced the risk of disease recurrence 68% compared with the control arm in topline results from the PIVOT-006 trial.
2The PIVOT-006 trial included 367 patients at about 90 centers in the United States and Canada.
3Median follow-up was 17 months as of October 26, 2026.
4CG Oncology shares rose 23.7% in premarket trading on November 16, 2026.

CG Oncology announced positive topline results on November 16, 2026, from PIVOT-006, a registrational Phase 3 trial of intravesical cretostimogene after tumor resection. The company said the treatment reduced the risk of disease recurrence 68% compared with the control arm, meeting the trial’s primary endpoint. The study covers patients with intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer. The announcement puts the trial data at the forefront of the company’s clinical program, while the results remain preliminary and the drug is still under investigation. The results do not mean regulatory approval or commercial availability of the treatment.

The hazard ratio was 0.32, with a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001, according to the company’s statement. These measures describe the comparison between the treatment group and the control arm over the study period, while the company said the analysis met the trial’s primary endpoint. Median follow-up reached 17 months as of October 26, 2026. This means the announced results are based on tracking participants over a defined period, and the data may continue to mature as follow-up extends. The company said, "Cretostimogene led to a 68% reduction in the risk of disease recurrence compared with the control arm."

PIVOT-006 included about 367 patients at nearly 90 centers in the United States and Canada, according to the company. The trial compared intravesical administration of the treatment with surveillance after complete tumor resection. The company described the study as one of the largest randomized Phase 3 trials conducted in patients with intermediate-risk non-muscle-invasive bladder cancer. The announced results target a group that includes intermediate-risk patients and patients with high-grade Ta disease, the group the company is working to include in a separate license application pathway. The company said this group comprises about 50,000 patients and that there are currently no FDA-approved adjuvant treatments for it.

Cretostimogene remains an investigational oncolytic immunotherapy administered intravesically, and its safety and efficacy have not been established by the U.S. Food and Drug Administration or any other health authority, according to the company. The company’s filing with the U.S. Securities and Exchange Commission reported no treatment-related adverse events of Grade 3 or higher in PIVOT-006. Treatment-related events also did not lead to discontinuation. These data provide an initial account of safety in the trial, alongside the efficacy result announced by the company. Any subsequent therapeutic use would require the regulatory pathway and review by the relevant authorities.

The announcement was accompanied by a reaction in premarket trading, with Investing.com reporting that CG Oncology shares rose 23.7% in that trading on November 16 after the results were published. The company’s shares, listed under the ticker CGON, had closed at $74.4 on November 13, according to EL7 data. The previous closing price does not represent the share price after the results announcement, and premarket trading does not determine the November 16 session close. On the financial front, the company said in its third-quarter filing that cash, cash equivalents and marketable securities totaled $984.5 million on September 30. It added that it expects these resources to fund operations through 2029.

The company is scheduled to present the topline results in a late-breaking session at the annual meeting of the Society of Urologic Oncology on December 2, 2026. On the regulatory front, it expects to complete a biologics license application by the end of March 2027 for patients with non-muscle-invasive bladder cancer unresponsive to BCG therapy, expanding the application to include only high-grade papillary disease. The company plans to seek a second license for the intermediate-risk and high-grade Ta group in the second quarter of 2027. Chief Executive Arthur Kwan said the company is working to complete this application during the second quarter. The company also expects 12-month follow-up data from the BOND-003 and CORE-008 cohorts in December 2026.

Open on chart